The estimated impact of state‐level support for expanded delivery of substance use disorder treatment during the COVID‐19 pandemic. (27th December 2021)

• Record Type: Journal Article
• Authors: Nesoff, Elizabeth D.; Marziali, Megan E.; Martins, Silvia S.
• Is Part Of: Addiction. Volume 117:Number 6(2022)
• Page Start: 1781
• Page End: 1786
• Publication Date: 2021-12-27
• Subjects: COVID‐19 -- medication for opioid use disorders -- policy -- substance use disorder -- substance use treatment -- unmet treatment need; Alcoholism -- Periodicals; Drug addiction -- Periodicals; 616.86
• DOI: 10.1111/add.15778
• Languages: English
• ISSNs: 0965-2140

Abstract

Abstract: Background and Aims: To prevent COVID‐19 transmission, some United States (US) federal regulations on substance use disorder (SUD) treatment were suspended in March 2020. This study aimed to quantify the extent of state‐level policy uptake and the potential number of people with SUD affected by these policy changes across the US, as well as to assess if policy uptake correlated with rates of people with SUD already in treatment or needing treatment. Design: Cross‐sectional analysis of policies implemented as of April 13, 2020. Setting and Participants: A total of 50 US states and the District of Columbia Measurements: State‐level implementation of: oral schedule II controlled substances emergency prescription, extended take‐home doses for medication for opioid use disorders (MOUD), home‐delivery of take‐home medications, telemedicine for schedule II‐IV prescriptions, telemedicine for buprenorphine prescribing initiation, and waiver of out‐of‐state Drug Enforcement Administration (DEA) registration. Rates per 100 000 population of: adults in treatment for SUD, MOUD treatment at facilities with opioid treatment programs, SUD based on Diagnostic and Statistical Manual of Mental Disorders (DSM)‐IV criteria, and needing, but not receiving treatment. Findings: Half of the states ( n = 24) enacted no policies, leaving ~460 955 people in treatment and 114 370 people on MOUD pre‐pandemic uncovered by any policy expansion. Only telemedicine for buprenorphine initiation was marginally associated with pre‐pandemic rate of SUD treatment (OR = 1.003, 95% CI = [1.001, 1.006]) and rate of MOUD therapy (OR = 1.006, 95% CI = [1.002, 1.011]) in univariable analysis, but these associations were no longer significant when controlling for state‐level demographics. No policies were associated with state‐wide SUD prevalence or rate of unmet treatment need ( P > 0.05). Conclusions: Twenty‐four United States states did not implement at least one federal policy for substance use disorder treatment expansion as of April 2020, leaving approximately half a million people in treatment pre‐pandemic potentially without access to treatment or risking exposure to COVID‐19 to continue in‐person therapies.